Thrombolysis outcomes according to arterial characteristics of acute ischemic stroke by alteplase dose and blood pressure target

Background We explored the influence of low-dose intravenous alteplase and intensive blood pressure lowering on outcomes of acute ischemic stroke according to status/location of vascular obstruction in participants of the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED). Methods ENCHANTED was a multicenter, quasi-factorial, randomized trial to determine efficacy and safety of low- versus standard-dose intravenous alteplase and intensive- versus guideline-recommended blood pressure lowering in acute ischemic stroke patients. In those who had baseline computed tomography or magnetic resonance imaging angiography, the degree of vascular occlusion was grouped according to being no (NVO), medium (MVO), or large (LVO). Logistic regression models were used to determine 90-day outcomes (modified Rankin scale [mRS] shift [primary], other mRS cut-scores, intracranial hemorrhage, early neurologic deterioration, and recanalization) by vascular obstruction status/site. Heterogeneity in associations for outcomes across subgroups was estimated by adding an interaction term to the models. Results There were 940 participants: 607 in alteplase arm only, 243 in blood pressure arm only, and 90 assigned to both arms. Compared to the NVO group, functional outcome was worse in LVO (mRS shift, adjusted OR [95% CI] 2.13 [1.56–2.90]) but comparable in MVO (1.34 [0.96–1.88]) groups. There were no differences in associations of alteplase dose or blood pressure lowering and outcomes across NVO/MVO/LVO groups (mRS shift: low versus standard alteplase dose 0.84 [0.54–1.30]/0.48 [0.25–0.91]/0.99 [0.75–2.09], Pinteraction = 0.28; intensive versus standard blood pressure lowering 1.32 [0.74–2.38]/0.78 [0.31–1.94]/1.24 [0.64–2.41], Pinteraction = 0.41), except for a borderline significant difference for intensive blood pressure lowering and increased early neurologic deterioration (0.63 [0.14–2.72]/0.17 [0.02–1.47]/2.69 [0.90–8.04], Pinteraction = 0.05). Conclusions Functional outcome by dose of alteplase or intensity of blood pressure lowering is not modified by vascular obstruction status/site according to analyses from ENCHANTED, although these results are compromised by low statistical power. Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifiers: NCT01422616

[1]  A. Rai,et al.  Intravenous Thrombolysis Outcomes in Patients Presenting with Large Vessel Acute Ischemic Strokes—CT Angiography‐Based Prognosis , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[2]  S. M. Park,et al.  Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. , 2019, Lancet.

[3]  P. Barber,et al.  The Benefits of Intravenous Thrombolysis Relate to the Site of Baseline Arterial Occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) , 2010, Stroke.

[4]  C. Molina,et al.  Frequency and outcome of total anterior circulation strokes without intracranial large‐vessel occlusion , 2017, European journal of neurology.

[5]  M. Woodward,et al.  Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study) , 2017, Stroke.

[6]  M. Woodward,et al.  Intensive versus guideline‐recommended blood pressure reduction in acute lacunar stroke with intravenous thrombolysis therapy: The ENCHANTED trial , 2020, European journal of neurology.

[7]  Maheshwari Patel,et al.  Study , 2019, Definitions.

[8]  C. Matouk,et al.  Decreases in Blood Pressure During Thrombectomy Are Associated With Larger Infarct Volumes and Worse Functional Outcome. , 2019, Stroke.

[9]  K. Kimura,et al.  Intravenous Tissue Plasminogen Activator Thrombolysis in Patients without Major Arterial Occlusion Seems to Be Safe and Effective , 2010, European Neurology.

[10]  T. Haarmeier,et al.  Time is brain , 2011, Der Nervenarzt.

[11]  G. Tsivgoulis,et al.  Internal Carotid Artery Occlusion: Pathophysiology, Diagnosis, and Management , 2017, Current Atherosclerosis Reports.

[12]  P. Sandercock,et al.  Arterial Obstruction on Computed Tomographic or Magnetic Resonance Angiography and Response to Intravenous Thrombolytics in Ischemic Stroke , 2016, Stroke.

[13]  Thalia Shoshana Field,et al.  Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke , 2018, JAMA.

[14]  A. Demchuk,et al.  CT Angiography Clot Burden Score and Collateral Score: Correlation with Clinical and Radiologic Outcomes in Acute Middle Cerebral Artery Infarct , 2009, American Journal of Neuroradiology.

[15]  A. Demchuk,et al.  Multiphase CT Angiography: A New Tool for the Imaging Triage of Patients with Acute Ischemic Stroke. , 2015, Radiology.

[16]  Mark Woodward,et al.  Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. , 2016, The New England journal of medicine.

[17]  A. Demchuk,et al.  Clinical Course of Acute Ischemic Stroke Due to Medium Vessel Occlusion With and Without Intravenous Alteplase Treatment , 2020, Stroke.

[18]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[19]  A. Demchuk,et al.  From “Time is Brain” to “Imaging is Brain”: A Paradigm Shift in the Management of Acute Ischemic Stroke , 2020, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[20]  C. Anderson,et al.  Brain imaging abnormalities and outcome after acute ischaemic stroke: the ENCHANTED trial , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.